Compositions and methods related to anti-FGF agents
View Patent ↗The invention relates to an isolated amino acid that can act as an antagonist to FGF signaling, comprising at least a portion of the FGF protein amino acid sequence, and including a mutation in either a) the integrin αvβ3 binding region of FGF-1; or b) the FGFR binding region of FGF-1.
1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutation R50E.
2. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutations E101A, Y109A, and N110A.
3. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutations K127E, K128E, K133E, and R134E.
4. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutation N33A.
5. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutation R50Q.
6. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has a mutation in the region Arg-50, Asp-51, Arg-52.
7. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutations K127Q and K128Q.
8. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7, wherein the amino acid sequence of SEQ ID NO:7 has amino acid mutations K133Q and R134Q.
9. A pharmaceutical composition comprising the polypeptide of any one of claims 1 - 8 and a carrier.